INHIBITORS OF CYCLIC NUCLEOTIDE SYNTHESIS AND THIER USE

 

 Market:  The excessive production of cyclic nucleotides such as cGMP and cAMP is important for pathogenesis of many diseases.  Diarrhea in humans and animals can be mediated by elevation in cGMP induced by toxins of various pathogenic bacteria.  The need for novel therapies for both the human and veterinary medical fields is tremendous.  Diarrheal diseases are the leading causes of death throughout the world, especially in children in developing countries.  The economic impact of diarrhea diseases in newborn livestock is also substantial. The toxic effect of edema factor of B. anthracis is mediated by cAMP and while antibiotics kill the organism itself, it is often the accumulated edema factor that causes sickness and death. Other pathogens such as Bordetella pertussis and Yersinia pestis also have a component of their pathology associated with elevation of cyclic nucleotides.  A broad based inhibitor of the nucleotide cyclases could have a multitude of indications and play a critical role in the treatment of various diseases.

 

The Technology:  The inventors have identified and validated a class of compounds that inhibit the formation of both cGMP and cAMP.  The inventors have tested the compounds in a variety of animal models where they have shown therapeutic effect for treating diarrhea, anthrax, whooping cough.

 

NON-CONFIDENTIAL TECHNOLOGY DESCRIPTION

The preceding is intended to be a non-confidential summary of a novel technology created at the University of Texas Health Science center at Houston (UTHSCH), for which the University has obtained patent protection. 

UTHSCH Ref. No. 2006-0022

Inventors: Drs. Murad, Kots and Choi

Patent Status: Pending

License Available: world-wide; exclusive or non-exclusive

 

To obtain further information about this technology, please contact:
Office of Technology Management, 7000 Fannin, Suite 720, Houston, TX 77030
Phone: (713) 500-3369  Fax: (713) 500-0331
Email: uthsch-otm@uth.tmc.edu